Posted on January 23, 2026
This January, OPM Biosciences is pleased to welcome PharmaLegacy, a leading contract research organization (CRO) specializing in preclinical pharmacology and efficacy evaluation, to the OPM family.
Together, we are strengthening our ability to support global drug makers with critical raw materials and integrated contract research, development, and manufacturing organization (CRDMO) services, accelerating high-quality R&D and manufacturing across the biopharmaceutical value chain.
Founded in 2008, PharmaLegacy has built a strong reputation as a premier CRO with deep expertise in preclinical pharmacology, pharmacokinetics, and safety evaluation. Its comprehensive services span drug discovery and early-stage screening, in vitro and in vivo pharmacology, drug metabolism and pharmacokinetics (DMPK), GLP toxicology, and Class III medical device evaluation.
To date, PharmaLegacy has partnered with thousands of leading pharmaceutical and biotechnology companies and supported 700+ new drug filing projects. The company has established 1,800+ disease models across multiple species, covering a broad range of therapeutic areas including autoimmune and inflammatory diseases, oncology, metabolic disorders, and cardiovascular diseases.
By joining forces, OPM Biosciences and PharmaLegacy unlock powerful synergies across portfolios, customers, global strategy, and operations—creating a more seamless pathway from early research to commercial production.
OPM brings established strengths in cell culture media and biologics Development (D) and Manufacturing (M), supporting programs from R&D through commercialization. PharmaLegacy complements this with a strong foundation in Research (R), particularly in preclinical pharmacology, along with a robust early-stage pipeline and an innovation-driven customer base.
This collaboration marks a strategic evolution—from standalone services to an integrated, end-to-end value chain. By combining PharmaLegacy’s research expertise with OPM’s media products and CDMO capabilities, we are building a unified “Media + CRDMO” platform that improves R&D efficiency and shortens timelines for our customers.
Our shared vision is clear: to integrate best-in-class products and services into a fully connected biopharmaceutical innovation platform spanning research, development, manufacturing, and global commercialization.
By enabling seamless end-to-end solutions, OPM Biosciences and PharmaLegacy are committed to becoming trusted partners for biopharmas worldwide—bringing transformative therapies to patients faster.